Vanguard CIV H3N2/H3N8 Canine Influenza Vaccine
فانجارد سي آي في لقاح إنفلونزا الكلاب الثنائي المعطل
Vanguard CIV H3N2/H3N8 is a bivalent, inactivated (killed virus) canine influenza vaccine containing viral cultures of Canine Influenza Virus subtypes H3N2 and H3N8, formulated with an adjuvant. Indicated for the vaccination of healthy dogs 8 weeks of age or older as an aid in controlling disease associated with canine influenza virus infection, significantly reducing severity of clinical coughing and lung lesions.
Dosage Form
Injection
Product Type
Biological
Manufacturer
Package
Cartons of 25 x 1-dose vials (1 mL each)
Dosages
| Species | Dosage | Route | Duration |
|---|---|---|---|
| Dog | 1 mL administered subcutaneously | Subcutaneous (SC) | Initial series of 2 doses administered 3 weeks apart; revaccinate annually |
Withdrawal Periods
No withdrawal information available.
Indications
-
Vaccination of healthy dogs 8 weeks of age or older as an aid in the control of disease associated with Canine Influenza Virus subtypes H3N2 and H3N8.
Contraindications
-
Do not vaccinate clinically ill or febrile dogs.
Precautions
-
Contains gentamicin and thimerosal as preservatives. Epinephrine should be available in case of allergic anaphylaxis.
Side Effects
-
Transient local swelling or mild tenderness at the injection site lasting 24-48 hours.
Images
Documents
-
Download
Vanguard CIV H3N2/H3N8 Canine Influenza Vaccine Prescribing Information
Leaflet
Active Ingredients
Diseases
No diseases linked.
Related Products
No data available
Information has not been added yet.
Related Products By Active Ingredient
No data available
Information has not been added yet.
Companies
-
Zoetis
Manufacturer
Alternatives
No alternatives available.